Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.34B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 9.92M
Average 4.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +64.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +64.1% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Edgewise Therapeutics, Inc. NASDAQ:EWTX | $4.94B | $45.93 | Not rated | -21.9 | +84.29% |
AbCellera Biologics Inc. NASDAQ:ABCL | $3.75B | $11.49 | Not rated | -11.4 | +190.03% |
Viridian Therapeutics, Inc. NASDAQ:VRDN | $3.51B | $30.87 | Not rated | -4.7 | +9.62% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | $28.83 | Not rated | -7.8 | +12.20% |
Aurinia Pharmaceuticals Inc. NASDAQ:AUPH | $2.11B | $15.73 | Undervalued | 7.2 | -2.04% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -6.30% |
uniQure N.V. NASDAQ:QURE | $1.67B | $23.81 | Not rated | -14.1 | -27.62% |
Ocular Therapeutix, Inc. NASDAQ:OCUL | $1.37B | $6.21 | Not rated | -7.3 | -51.57% |
Structure Therapeutics Inc. NASDAQ:GPCR | $1.15B | $20.00 | Not rated | -19.3 | -53.11% |
Janux Therapeutics, Inc. NASDAQ:JANX | $695.66M | $11.37 | Not rated | -7.6 | -64.28% |
Continue the stock analysis
Jump to another research area for this company.